Literature DB >> 18467290

Rules of tumor cell development and their application to biomarkers for ovarian cancer.

Monica R McLemore1, Christine Miaskowski, Bradley E Aouizerat, Lee-may Chen, Marylin Dodd.   

Abstract

PURPOSE/
OBJECTIVES: To apply the Hanahan and Weinberg conceptual framework for tumor development to the specific biomarkers observed or expressed in ovarian cancer. DATA SOURCES: Data-based publications, topical reviews, and book chapters. DATA SYNTHESIS: Articles specific to ovarian cancer were reviewed to examine whether the six rules from the Hanahan and Weinberg conceptual framework were applicable to biomarkers of ovarian cancer. This approach allows for the application of a general framework for the development of solid tumors to the development of ovarian cancer.
CONCLUSIONS: The six rules for tumor cell development outlined in the Hanahan and Weinberg conceptual framework are applicable to biomarkers expressed or observed in patients with ovarian cancer. IMPLICATIONS FOR NURSING: Oncology nurses can enhance their clinical teaching by integrating this information into their practice. Nurses who conduct research on ovarian cancer can use this framework to guide the selection of biomarker(s) for these studies. Finally, nurse educators can use this framework when teaching students key concepts in the care of patients with cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18467290     DOI: 10.1188/08.ONF.403-409

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  2 in total

Review 1.  Protein biomarkers of ovarian cancer: the forest and the trees.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Future Oncol       Date:  2012-01       Impact factor: 3.404

2.  Id2 promotes the invasive growth of MCF-7 and SKOV-3 cells by a novel mechanism independent of dimerization to basic helix-loop-helix factors.

Authors:  Yuanguang Meng; Chenglei Gu; Zhiqiang Wu; Yali Zhao; Yiling Si; Xiaobing Fu; Weidong Han
Journal:  BMC Cancer       Date:  2009-03-04       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.